ALIM - Alimera Sciences, Inc. Stock Price and Quote

ALIM [NASD]

Healthcare | Drug Manufacturers - Specialty & Generic | USA

Index	-	P/E	-	EPS (ttm)	-2.64	Insider Own	3.00%	Shs Outstand	7.00M	Perf Week	-10.38%
Market Cap	11.63M	Forward P/E	-	EPS next Y	-0.66	Insider Trans	0.00%	Shs Float	5.62M	Perf Month	-33.06%
Income	-18.40M	PEG	-	EPS next Q	-0.34	Inst Own	30.60%	Short Float / Ratio	0.41% / 2.05	Perf Quarter	-27.11%
Sales	54.10M	P/S	0.21	EPS this Y	36.50%	Inst Trans	3.43%	Short Interest	0.02M	Perf Half Y	-70.61%
Book/sh	-5.33	P/B	-	EPS next Y	72.30%	ROA	-37.00%	Target Price	6.75	Perf Year	-69.17%
Cash/sh	0.78	P/C	2.11	EPS next 5Y	-	ROE	62.20%	52W Range	1.57 - 7.92	Perf YTD	-39.48%
Dividend	-	P/FCF	-	EPS past 5Y	-1.10%	ROI	5.30%	52W High	-79.29%	Beta	1.42
Dividend %	-	Quick Ratio	0.80	Sales past 5Y	11.40%	Gross Margin	85.50%	52W Low	4.46%	ATR	0.17
Employees	145	Current Ratio	0.90	Sales Q/Q	11.50%	Oper. Margin	-22.60%	RSI (14)	30.63	Volatility	5.81% 8.33%
Optionable	No	Debt/Eq	-	EPS Q/Q	-24.40%	Profit Margin	-34.10%	Rel Volume	0.00	Prev Close	1.64
Shortable	Yes	LT Debt/Eq	-	Earnings	-	Payout	-	Avg Volume	11.19K	Price	1.64
Recom	2.30	SMA20	-18.19%	SMA50	-31.79%	SMA200	-63.51%	Volume	0	Change	0.00%

May-28-19

Initiated

Craig Hallum

Buy

Apr-27-17

Initiated

Rodman & Renshaw

Buy

Nov-17-14

Initiated

Summer Street Research

Buy

$12

Sep-29-14

Reiterated

Northland Capital

Outperform

$7 → $10

Oct-28-13

Upgrade

Cowen

Market Perform → Outperform

Oct-08-13

Initiated

Northland Capital

Outperform

Nov-14-11

Downgrade

Rodman & Renshaw

Mkt Outperform → Mkt Perform

Dec-27-10

Reiterated

Oppenheimer

Outperform

$16 → $14

Oct-11-10

Initiated

Rodman & Renshaw

Mkt Outperform

$13

Jun-02-10

Initiated

Oppenheimer

Outperform

$16

Feb-27-23 08:00AM	Alimera Appoints Roger Sawhney, M.D. to Its Board of Directors GlobeNewswire
Feb-22-23 08:00AM	Alimera Announces Submission of Marketing Authorization Application in Switzerland for ILUVIEN® GlobeNewswire -5.44%
Jan-09-23 08:00AM	Alimera Sciences Appoints Industry Veteran Russell L. Skibsted as Chief Financial Officer GlobeNewswire
Dec-29-22 06:02AM	Alimera Sciences, Inc. (NASDAQ:ALIM) Q3 2022 Earnings Call Transcript Insider Monkey +10.76%
Dec-08-22 08:00AM	Alimera Sciences Announces Agreement to Extend Amortization Date and Interest-Only Period on Loan Agreement GlobeNewswire
08:00AM	Loading…
Nov-29-22 08:00AM	Alimera Highlights Abstracts Regarding Consensus Among US Retina Specialists and Reduced Retinal Thickness Variability Leading to Improved Visual Outcomes Following ILUVIEN® Administration GlobeNewswire
Nov-17-22 03:54PM	7 Stocks That Could Implode at Any Moment InvestorPlace
Nov-16-22 05:05AM	Alimera Sciences Third Quarter 2022 Earnings: Misses Expectations Simply Wall St. -9.38%
Nov-14-22 08:55AM	Alimera Sciences (ALIM) Reports Q3 Loss, Lags Revenue Estimates Zacks
07:30AM	Alimera Sciences Announces Third Quarter 2022 Financial Results GlobeNewswire
Nov-02-22 08:00AM	Alimera Sciences to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022, and Provide Corporate Update GlobeNewswire
Nov-01-22 08:00AM	Alimera Announces Reimbursement of Uveitis Indication Granted for ILUVIEN® in the Czech Republic GlobeNewswire
Oct-20-22 09:40AM	Is Alimera Sciences (ALIM) Stock Outpacing Its Medical Peers This Year? Zacks
Oct-18-22 09:03AM	10 Best Low Price Pharma Stocks To Buy Now Insider Monkey +6.11%
Oct-06-22 08:00AM	Paladin Phase 4 Study Confirms ILUVIEN® Patients' Reduced Need for Multiple Treatments GlobeNewswire +6.81%
08:00AM	Loading…
Sep-23-22 08:00AM	Alimera Announces Agreement with Jaeb Center for Health Research on Behalf of the DRCR Retina Network GlobeNewswire
Sep-20-22 08:00AM	Alimera Announces Reimbursement of Uveitis Indication Granted for ILUVIEN® in Ireland GlobeNewswire
Sep-19-22 09:40AM	Are Medical Stocks Lagging Alimera Sciences (ALIM) This Year? Zacks
Sep-02-22 09:40AM	Is Humana (HUM) Stock Outpacing Its Medical Peers This Year? Zacks
Aug-31-22 08:48AM	Alimera Announces Multiple Abstracts Highlighting ILUVIEN® Real World Data at EURETINA Annual Congress GlobeNewswire
Aug-29-22 08:50AM	Why Fast-paced Mover Alimera Sciences (ALIM) Is a Great Choice for Value Investors Zacks
Aug-19-22 08:50AM	Alimera Sciences (ALIM) Is a Great Choice for "Trend" Investors, Here's Why Zacks +5.78%
Aug-17-22 09:40AM	Is Alimera Sciences (ALIM) Outperforming Other Medical Stocks This Year? Zacks
Aug-10-22 08:00AM	Alimera Sciences to Present at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference GlobeNewswire
Aug-09-22 08:00AM	Alimera Announces Reimbursement of Uveitis Indication Granted for ILUVIEN® in Portugal GlobeNewswire -5.59%
06:47AM	Investors in Alimera Sciences (NASDAQ:ALIM) from five years ago are still down 68%, even after 32% gain this past week Simply Wall St.
Aug-05-22 08:50AM	Here Is Why Bargain Hunters Would Love Fast-paced Mover Alimera Sciences (ALIM) Zacks
Aug-01-22 09:40AM	Has Alimera Sciences (ALIM) Outpaced Other Medical Stocks This Year? Zacks
Jul-27-22 08:45AM	Alimera Sciences (ALIM) Reports Q2 Loss, Tops Revenue Estimates Zacks +6.60%
07:30AM	Alimera Sciences Announces Second Quarter 2022 Financial Results GlobeNewswire
08:00AM	Loading…
Jul-26-22 08:00AM	Paladin Phase 4 Study Confirms Safety of Durable ILUVIEN® Treatment and Reduces Burden of Care For DME Patients GlobeNewswire
Jul-22-22 10:34AM	Alimera Sciences to Report Second Quarter 2022 Financial Results on Wednesday, July 27, 2022, and Provide Corporate Update GlobeNewswire
08:00AM	Alimera Announces Pricing and Reimbursement of Uveitis Indication Granted for ILUVIEN® in France GlobeNewswire
Jul-13-22 08:00AM	Alimera Announces Data to Be Highlighted In Scientific Programming At Annual Congress GlobeNewswire
Jul-08-22 08:00AM	Alimera Announces Approval and Pricing Granted for ILUVIEN® for Uveitis in Italy GlobeNewswire
Jun-24-22 07:10AM	A number of insiders bought Alimera Sciences, Inc. (NASDAQ:ALIM) stock last year, which is great news for shareholders Simply Wall St.
Jun-08-22 08:03AM	Phase III Clinical Study IND Accepted in China for Alimeras Fluocinolone Acetonide Intravitreal Implant GlobeNewswire
Jun-02-22 08:00AM	Alimera Sciences to Present at the LD Micro Invitational XII Conference GlobeNewswire
May-12-22 08:03AM	Phase 4 PALADIN Study Confirms Positive Predictive Value of Corticosteroid Course Prior to ILUVIEN® Use for IOP Outcomes GlobeNewswire
May-09-22 09:15AM	Alimera Sciences (ALIM) Reports Q1 Loss, Misses Revenue Estimates Zacks -7.34%
08:00AM	Alimera Sciences Reports First Quarter 2022 Results GlobeNewswire
May-06-22 08:00AM	Alimera Sciences to Report First Quarter 2022 Financial Results on Monday, May 9, 2022, and Provide Corporate Update GlobeNewswire -6.52%
07:45AM	Ocugen (OCGN) Reports Q1 Loss, Misses Revenue Estimates Zacks
May-05-22 05:55PM	Celldex Therapeutics (CLDX) Reports Q1 Loss, Misses Revenue Estimates Zacks +6.97%
Apr-28-22 08:30AM	Recent Alimera Data Featured in Scientific Programming at Upcoming Annual Congress GlobeNewswire +5.05%
Apr-26-22 07:24AM	New Strong Sell Stocks for April 26th Zacks
Apr-06-22 08:00AM	Alimera Exhibits Continued Growth and Expansion With New Branding and Office Relocation GlobeNewswire
Mar-31-22 08:15AM	Trevena (TRVN) Reports Q4 Loss, Lags Revenue Estimates Zacks +7.07%
Mar-30-22 05:44AM	New Strong Sell Stocks for March 30th Zacks -5.60%
Mar-28-22 10:48AM	New Strong Sell Stocks for March 28th Zacks
Mar-02-22 08:00AM	Alimera Sciences to Present at the Q1 Investor Summit Conference GlobeNewswire
Mar-01-22 08:35AM	New Strong Sell Stocks for March 1st Zacks
Feb-24-22 09:25AM	Alimera Sciences (ALIM) Reports Q4 Loss, Misses Revenue Estimates Zacks
08:00AM	Alimera Sciences Reports Fourth Quarter and FY 2021 Results GlobeNewswire
Feb-23-22 08:00AM	Phase 4 PALADIN Study with ILUVIEN® Published in Peer-Reviewed Journal Ophthalmology GlobeNewswire
Feb-17-22 08:00AM	Alimera Sciences to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, February 24, 2022, and Provide Corporate Update GlobeNewswire
Feb-07-22 08:00AM	Alimera Sciences Announces Launch of ILUVIEN® for Uveitis in Spain GlobeNewswire +5.58%
Feb-04-22 08:00AM	Alimera Sciences to Present at the MicroCap Rodeo Winter Wonderland Best Ideas Virtual Investor Conference GlobeNewswire -6.52%
Jan-28-22 10:07AM	36 of the Best Ideas Companies to Present at the 2nd Annual Winter Wonderland Virtual Investor Conference on February 8th - 11th, 2022 ACCESSWIRE +11.66%
Jan-05-22 08:00AM	Alimera Sciences to Participate in Upcoming January 2022 Investor Conferences GlobeNewswire
Dec-01-21 07:30AM	Alimera Sciences Welcomes Ophthalmic Strategic Consultant Erin Parsons to Its Board of Directors GlobeNewswire
Nov-09-21 01:16PM	Alimera Sciences to Participate in Upcoming November 2021 Investor Conferences GlobeNewswire -7.06%
Nov-06-21 08:15AM	Insiders who bought Alimera Sciences, Inc. (NASDAQ:ALIM) last year must be regretting not buying more as market cap hits US$39m Simply Wall St.
Nov-05-21 10:03AM	3 Penny Stocks Insiders Are Buying Benzinga +26.67%
Oct-28-21 06:01PM	Alimera Sciences, inc (ALIM) Q3 2021 Earnings Call Transcript Motley Fool +5.10%
08:55AM	Alimera Sciences (ALIM) Reports Q3 Loss, Misses Revenue Estimates Zacks
07:30AM	Alimera Sciences Announces Third Quarter 2021 Financial Results GlobeNewswire
Oct-21-21 08:00AM	Alimera Sciences to Report Third Quarter 2021 Financial Results on Thursday, October 28, 2021, and Provide Corporate Update GlobeNewswire
Oct-20-21 03:02PM	Analysts Estimate Alimera Sciences (ALIM) to Report a Decline in Earnings: What to Look Out for Zacks
Oct-13-21 08:00AM	Recent 24-Month Real-World PALADIN Data Demonstrate the Ability of ILUVIEN® to Significantly Reduce Treatment Burden in Patients with Diabetic Macular Edema GlobeNewswire +6.08%
Sep-02-21 04:30PM	Alimera Sciences, Inc. to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference GlobeNewswire
Aug-24-21 08:00AM	Alimera Sciences Announces National Pricing and Reimbursement Granted for ILUVIEN® for DME in Belgium GlobeNewswire +5.11%
Aug-13-21 12:00PM	Alimera Sciences, inc (ALIM) Q2 2021 Earnings Call Transcript Motley Fool -14.00%
09:25AM	Alimera Sciences (ALIM) Q2 Earnings and Revenues Miss Estimates Zacks
08:00AM	Alimera Sciences Announces Second Quarter 2021 Financial Results GlobeNewswire
Aug-10-21 08:00AM	Alimera Sciences to Report Second Quarter 2021 Financial Results on Friday, August 13, 2021, and Provide Corporate Update GlobeNewswire
Aug-09-21 08:00AM	Alimera Sciences and Tanner Pharma Group Initiate Global Named Patient Program for ILUVIEN® GlobeNewswire +5.91%
Jul-28-21 03:03PM	Alimera Sciences (ALIM) Earnings Expected to Grow: Should You Buy? Zacks
Jun-05-21 04:22AM	Investors Who Bought Alimera Sciences (NASDAQ:ALIM) Shares A Year Ago Are Now Up 104% Simply Wall St.
May-27-21 07:15PM	35 of the Best Ideas Companies to Present at the Summer Solstice - Best Ideas from the Buy-Side Virtual Investor Conference on June 1-4, 2021 ACCESSWIRE
08:15AM	Alimera Sciences, Inc. to Present at the Summer Solstice Best Ideas from the Buy Side Conference on June 2, 2021 GlobeNewswire
May-17-21 08:12AM	Alimera Sciences Appoints David Dyer, M.D. as Chief Retina Specialist GlobeNewswire
Apr-29-21 03:30PM	Alimera Sciences Inc (ALIM) Q1 2021 Earnings Call Transcript Motley Fool -9.46%
06:45AM	Alimera Sciences, Inc. to Host Earnings Call ACCESSWIRE
Apr-28-21 07:25PM	Alimera Sciences (ALIM) Reports Q1 Loss, Lags Revenue Estimates Zacks
04:32PM	Alimera Sciences Announces First Quarter 2021 Financial Results GlobeNewswire
Apr-26-21 10:51AM	Alimera Science's Innovative Treatment for Diabetic Macular Edema Vision Loss Lasts for up to 3 Years Benzinga
Apr-22-21 08:00AM	Alimera Sciences to Report First Quarter 2021 Financial Results on Wednesday, April 28, 2021 and Provide Corporate Update GlobeNewswire
Apr-14-21 10:34AM	Alimera, Ocumension Ink Licensing Pact For Fluocinolone Acetonide Eye Implant In China Benzinga +6.30%
09:00AM	Alimera Sciences Receives $20 Million From Ocumension Therapeutics GlobeNewswire
Apr-09-21 08:00AM	Alimera Sciences to Present at the Zooming with LD Micro Virtual Conference on April 15, 2021 GlobeNewswire
Mar-18-21 08:00AM	Alimera Sciences to Participate in Benzinga Biotech Small Cap Conference GlobeNewswire
Mar-17-21 08:00AM	Alimera Sciences Continues to Execute on Its Expansion Strategy in Denmark and Luxembourg, and Achieves Extended Reimbursement in Ireland GlobeNewswire
Mar-11-21 08:00AM	Alimera Sciences to Present at Maxim Groups Inaugural Emerging Growth Virtual Conference GlobeNewswire +22.44%
Mar-02-21 08:00AM	Alimera Sciences to Present at the H.C. Wainwright Global Life Sciences Conference GlobeNewswire +8.30%
Feb-25-21 03:30PM	Alimera Sciences Inc (ALIM) Q4 2020 Earnings Call Transcript Motley Fool -11.57%
Feb-24-21 04:05PM	Alimera Sciences Reports Fourth Quarter and 2020 Results GlobeNewswire +6.64%
Feb-18-21 10:57AM	Centric Financial Corporation Announces Earnings for 4th Quarter and Year End 2020 PR Newswire
08:30AM	Alimera Sciences Continues Global Geographic Expansion With Launch of ILUVIEN in Finland for Both Indications GlobeNewswire
Feb-17-21 08:30AM	Alimera Sciences to Report Fourth Quarter and Full Year 2020 Financial Results on Wednesday, February 24, 2021 and Provide Corporate Update GlobeNewswire

Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician offices, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. The company was incorporated in 2003 and is headquartered in Alpharetta, Georgia.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Upgrade your FINVIZ experience